Stay updated on MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Sign up to get notified when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.

Latest updates to the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe page adds footer-level metadata and regulatory context, including FDA-regulated notices, IPD planning, PubMed publications, and related topic links, enhancing access to regulatory information and related resources without altering the study details.SummaryDifference56%

- Check12 days agoChange DetectedThe page revision tag was updated to v3.6.5, indicating a minor update to the study record's metadata.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4. This appears to be a minor template or platform update with no changes to the study details or user interactions.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page revision updates to version v3.6.3, signaling a small update to the study record. There are no visible changes to the study details or user-facing information.SummaryDifference0.1%

- Check55 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a newer published version without describing substantive content changes.SummaryDifference0.1%

- Check70 days agoChange DetectedNew user guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the page revision shows Revision: v3.6.0. Additionally, the recruitment status was updated to 'No longer looking for participants', signaling that enrollment for this study has closed.SummaryDifference0.4%

Stay in the know with updates to MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MG1-MAGEA3 Combo with Pembrolizumab for NSCLC Clinical Trial page.